Scarica l'app Stockscreener
7.30
2.24%
0.16
Dopo l'orario di chiusura:
7.24
-0.06
-0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald
Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat
When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
NYSE: PINS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Pinterest, Inc. - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - PR Newswire
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN
ImmunityBio Sued for Securities Law Violations - National Today
ImmunityBio Faces Investor Lawsuit Over Cancer Drug Claims - AD HOC NEWS
ImmunityBio (IBRX) insider converts $25M note into 4.6M shares - Stock Titan
IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire Inc.
ImmunityBio (NASDAQ:IBRX) Trading 2.2% HigherTime to Buy? - MarketBeat
ImmunityBio: No Need To Rush Into Buying TodayWhy I'm Downgrading To Hold (NASDAQ:IBRX) - Seeking Alpha
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - GlobeNewswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion - Insider Monkey
IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter - Stocktwits
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - Bitget
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - insidermonkey.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Volatile Share Price Swings - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ImmunityBio (NASDAQ:IBRX) Shares Up 15.2%What's Next? - MarketBeat
Investors Seek Lead in ImmunityBio Class Action Lawsuit - National Today
Dunkirk pharma plant prepares to hire 100, kick off production - The Business Journals
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - PR Newswire
Investors Warned of Large Losses in ImmunityBio Stock - National Today
Why Are ImmunityBio Shares Rising Today? - Benzinga
Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec” - Yahoo Finance
Anktiva Gains Ground in Global Cancer Treatment Strategy - StocksToTrade
ImmunityBio strengthens balance sheet to fund Anktiva commercialization - The Pharma Letter
Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ImmunityBio plunges after getting FDA warning on cancer drug - msn.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) - TMX Newsfile
ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement - Insider Monkey
ImmunityBio Secures Major Milestone With ANKTIVA in Asia-Pacific Expansion - timothysykes.com
ImmunityBio Bolsters Balance Sheet With New Financing Moves - TipRanks
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):